42 results
8-K
EX-99.2
ABOS
Acumen Pharmaceuticals Inc
14 May 24
Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights
7:35am
delivery technology, ENHANZE®, is commercially validated in seven approved therapies, with global collaborations covering more than 60 therapeutic targets
8-K
EX-99.1
ABOS
Acumen Pharmaceuticals Inc
14 May 24
Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights
7:35am
biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD … developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD). Acumen’s
8-K
EX-99.1
ABOS
Acumen Pharmaceuticals Inc
26 Mar 24
Results of Operations and Financial Condition
7:42am
-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment … in Indianapolis, IN and Newton, MA, is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers
8-K
EX-99.1
ABOS
Acumen Pharmaceuticals Inc
19 Mar 24
Corporate Presentation March 2024 1
8:05am
therapies, with global collaborations covering more than 60 therapeutic targets Current sabirnetug potential target product profile inclusive
8-K
EX-99.1
c2i8321 z2f
1 Feb 24
Departure of Directors or Certain Officers
7:16am
8-K
EX-99.1
gy7rfyui
12 Jan 24
Corporate Presentation January 2024 1
8:42am
8-K
EX-99.1
kgep91a2x y5k9je6i
8 Jan 24
Regulation FD Disclosure
8:33am
8-K
EX-99.1
9gom31 xy
13 Nov 23
Acumen Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Highlights
7:20am
8-K
EX-99.2
kv7mdkxoif
13 Nov 23
Acumen Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Highlights
7:20am
8-K
EX-99.1
gy1l4x xv
8 Aug 23
Acumen Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business Highlights
7:33am
8-K
EX-99.1
bwnd7dh1k
17 Jul 23
Acumen Pharmaceuticals Presents Positive Topline Results from First-in-Human
6:06am
8-K
EX-99.1
libwl56fnn
9 May 23
Acumen Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Highlights
7:08am
8-K
EX-99.2
3i64ti4dgt8sa
9 May 23
Acumen Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Highlights
7:08am
8-K
EX-99.1
vbm 4fqbrycy84m28zpv
14 Nov 22
Acumen Pharmaceuticals Reports Third Quarter 2022
4:10pm
8-K
EX-99.2
s0w0g
14 Nov 22
Acumen Pharmaceuticals Reports Third Quarter 2022
4:10pm
8-K
nsu4yvmr3z2negdo
24 Oct 22
Acumen’s ACU193, an Anti-Amyloid Beta Oligomer Antibody, Granted
8:30am
8-K
EX-99.1
l6k9v68m0im
24 Oct 22
Acumen’s ACU193, an Anti-Amyloid Beta Oligomer Antibody, Granted
8:30am
8-K
EX-99.1
8p8 cvpdm89g3
12 Sep 22
Regulation FD Disclosure
8:30am